{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:48Z","timestamp":1792290768701,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tcm.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:51:01Z","timestamp":1729525861000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Guidelines for treating heart failure"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-2691","authenticated-orcid":false,"given":"Michelle M.","family":"Kittleson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.tcm.2024.10.002_bib0001","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.tcm.2024.10.002_bib0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2024.10.002_bib0003","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.tcm.2024.10.002_bib0004","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2024.10.002_bib0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2024.10.002_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tcm.2024.10.002_bib0007","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.1016\/j.tcm.2024.10.002_bib0008","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.tcm.2024.10.002_bib0009","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.tcm.2024.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tcm.2024.10.002_bib0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1016\/j.tcm.2024.10.002_bib0012","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tcm.2024.10.002_bib0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.tcm.2024.10.002_bib0015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2024.10.002_bib0016","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.tcm.2024.10.002_bib0017","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","article-title":"Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure","volume":"103","author":"Wallhaus","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.tcm.2024.10.002_bib0018","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"issue":"9146","key":"10.1016\/j.tcm.2024.10.002_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.tcm.2024.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"9266","key":"10.1016\/j.tcm.2024.10.002_bib0021","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2024.10.002_bib0022","first-page":"S53","article-title":"Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure","volume":"70","author":"Franz","year":"1992","journal-title":"Clin Investig"},{"key":"10.1016\/j.tcm.2024.10.002_bib0023","unstructured":"73 FR 77724 - Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; Availability: Office of the Federal Register, National Archives and Records Administration; 2008 [Available from: https:\/\/www.govinfo.gov\/app\/details\/FR-2008-12-19\/E8-30086."},{"issue":"7","key":"10.1016\/j.tcm.2024.10.002_bib0024","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.tcm.2024.10.002_bib0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tcm.2024.10.002_bib0026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.tcm.2024.10.002_bib0027","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.tcm.2024.10.002_bib0028","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.tcm.2024.10.002_bib0029","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tcm.2024.10.002_bib0030","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"issue":"9641","key":"10.1016\/j.tcm.2024.10.002_bib0031","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"issue":"9744","key":"10.1016\/j.tcm.2024.10.002_bib0032","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.tcm.2024.10.002_bib0033","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJM198611063151912","article-title":"Vasodilator therapy in congestive heart failure","volume":"315","year":"1986","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.tcm.2024.10.002_bib0034","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.tcm.2024.10.002_bib0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.tcm.2024.10.002_bib0036","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"10166","key":"10.1016\/j.tcm.2024.10.002_bib0037","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.tcm.2024.10.002_bib0038","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.tcm.2024.10.002_bib0039","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cardfail.2005.06.432","article-title":"The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design","volume":"11","author":"Carson","year":"2005","journal-title":"J Cardia Fail"},{"issue":"19","key":"10.1016\/j.tcm.2024.10.002_bib0040","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"issue":"9645","key":"10.1016\/j.tcm.2024.10.002_bib0041","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tcm.2024.10.002_bib0042","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002477","article-title":"Clinical phenotypes in heart failure with preserved ejection fraction","volume":"5","author":"Samson","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.tcm.2024.10.002_bib0044","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.tcm.2024.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.tcm.2024.10.002_bib0047","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.tcm.2024.10.002_bib0048","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","article-title":"Relation of loop diuretic dose to mortality in advanced heart failure","volume":"97","author":"Eshaghian","year":"2006","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.tcm.2024.10.002_bib0049","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.tcm.2024.10.002_bib0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1253\/circrep.CR-20-0041","article-title":"Empagliflozin administration can decrease the dose of loop diuretics and prevent the exacerbation of renal tubular injury in patients with compensated heart failure complicated by Diabetes","volume":"2","author":"Shirakabe","year":"2020","journal-title":"Circ Rep"},{"issue":"15","key":"10.1016\/j.tcm.2024.10.002_bib0051","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0052","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.tcm.2024.10.002_bib0053","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2024.10.002_bib0054","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2024.10.002_bib0055","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.tcm.2024.10.002_bib0056","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.tcm.2024.10.002_bib0057","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2024.10.002_bib0058","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"9386","key":"10.1016\/j.tcm.2024.10.002_bib0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.tcm.2024.10.002_bib0061","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.tcm.2024.10.002_bib0062","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.tcm.2024.10.002_bib0063","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.tcm.2024.10.002_bib0064","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"10456","key":"10.1016\/j.tcm.2024.10.002_bib0065","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.tcm.2024.10.002_bib0066","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0067","first-page":"56","article-title":"Loop diuretics in acute decompensated heart failure","volume":"2","author":"Felker","year":"2009","journal-title":"Circulat: Heart Fail"},{"issue":"1","key":"10.1016\/j.tcm.2024.10.002_bib0068","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cardfail.2015.07.007","article-title":"Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure","volume":"22","author":"Grodin","year":"2016","journal-title":"J Card Fail"},{"issue":"13","key":"10.1016\/j.tcm.2024.10.002_bib0069","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2024.10.002_bib0070","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet."},{"issue":"7","key":"10.1016\/j.tcm.2024.10.002_bib0071","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2024.10.002_bib0072","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.tcm.2024.10.002_bib0073","article-title":"Heart failure spending function: an investment framework for sequencing and intensification of guideline-directed medical therapies","volume":"15","author":"Allen","year":"2022","journal-title":"Circul: Heart Fail"},{"issue":"7","key":"10.1016\/j.tcm.2024.10.002_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100958","article-title":"Trajectories of sacubitril\/valsartan adherence among medicare beneficiaries with heart failure","volume":"3","author":"Huang","year":"2024","journal-title":"JACC Adv"},{"issue":"7","key":"10.1016\/j.tcm.2024.10.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.009179","article-title":"Relation of household income to access and adherence to combination sacubitril\/valsartan in heart failure: a retrospective analysis of commercially insured patients","volume":"15","author":"Johnson","year":"2022","journal-title":"Circ Cardiovasc Qual Outcom"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173824000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173824000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:53:29Z","timestamp":1743778409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173824000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1050173824000938"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2024.10.002","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines for treating heart failure","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}